SecBot SecBot
SC 13G ·Filed Nov 10, 2026

ARQT

Arcutis Biotherapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonimmediate Processed6d 19h ago SEC0000093751-26-000615
Passive investor 5%+ stake
Actionable Insight • Neutral

State Street's 6.1% passive stake is a routine institutional holding. Monitor for any future 13D conversion or significant share changes, but no near-term activist or control implications are indicated.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$27.39
T+0 close · Nov 10, 2026 · via day close
Latest settled
+3.63%
T+1 · $28.38
Vs SPY
+2.31%
α at T+1
Next horizon
T+5
in 5h
  1. T+0 · Nov 10 $27.39entry
  2. T+1 · 6d ago +3.63%α +2.31% · $28.38
  3. T+4 · todayOpen
  4. T+5 · in 5h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

State Street Corporation filed a Schedule 13G disclosing a 6.1% passive stake in Arcutis Biotherapeutics as of September 30, 2026, representing 7,718,628 shares. This is a routine passive ownership update with no change in investment intent, and the filing does not provide prior-period share counts for comparison.

Key Financial Metrics

Stake
6.1%
Investor
STATE STREET CORP

Key Facts

  • State Street Corporation disclosed a 6.1% passive beneficial ownership stake in Arcutis Biotherapeutics as of September 30, 2026.
  • The stake comprises 7,718,628 shares of common stock.
  • State Street certifies the shares were acquired and held in the ordinary course of business, not for changing or influencing control.
  • The filing is an initial Schedule 13G by State Street; no prior 13G from this filer is in the cross-filing context.

Financial Impact

6.1% passive stake valued at approximately $195M based on $3.2B market cap at analysis time.

ownership

Risk Factors

  • No material risks identified from this passive filing.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G Filing (Primary)0000093751-26-000615
Document: 0000093751-26-000615-index.html0000093751-26-000615
Document: 0000093751-26-000615.txt0000093751-26-000615

Track record

34 reports on ARQT

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +21.34% at T+60 after the Aug 5, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $28.26 Now $27.15 −3.93% settles Feb 11
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Viewing Entry $27.39 Now $27.15 −0.86% settles Feb 8
  3. Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $25.55 Now $27.15 +6.26% settles Feb 4
  4. Nov 4, 202612d ago 3/A / CLUSTER / 3 Neutral 2/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
  5. Nov 4, 202612d ago 144 Neutral 3/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
  6. Nov 4, 202612d ago 424B5 Bearish 4/10 Entry $27.00 Now $27.15 −0.56% settles Feb 3
  7. Nov 4, 202612d ago 8-K Neutral 5/10 No price data
  8. Nov 4, 202612d ago Press Release Mixed 6/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
  9. Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
  10. Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
Showing 10 of 34

US Market Status

Market Closed · Opens in 7h 28m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026